Acción RAC RACE ONCOLOGY LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Race Oncology Limited

Acciones

RAC

AU000000RAC3

Mercado cerrado - Australian S.E.
Otros sitios de cotización
 08:10:57 27/06/2024 		Varia. Cinco días. Varia. 1 de enero.
1,805 AUD -0,55 % Gráfico intradía de Race Oncology Limited -3,22 % +114,88 %
20/06 Race Oncology nombra a George Clinical para el ensayo de fase 1 del bisantreno RC220 MT
18/06 Race Oncology recibe la designación de enfermedad pediátrica rara de la FDA estadounidense para un medicamento contra la leucemia MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Race Oncology Concludes GLP Non-clinical Toxicology and Safety Pharmacology Studies for RC220 Bisantrene; Shares Jump 10%
Race Oncology Appoints George Clinical for RC220 Bisantrene Phase 1 Trial
Race Oncology Receives US FDA Rare Pediatric Disease Designation for Leukemia Medication
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%
Race Oncology Secures US FDA Orphan Drug Designation for Leukemia Medication; Shares Rise 5%
Race Oncology's breakthrough in cancer cell treatment
Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%
Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment
Race Oncology looks to accelerate clinical development of bisantrene
Race Oncology Widens Loss in Fiscal H1
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Race Oncology appoints Dr Daniel Tillett as CEO
Race Oncology Names CEO; Shares Jump 5%
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer
Race Oncology highlights impressive bisantrene clinical data
Race Oncology kicks off safety studies for RC220
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug
Race Oncology Limited(ASX:RAC) dropped from S&P Global BMI Index
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción RAC
  4. Noticias Race Oncology Limited
  5. Otros idiomas